NCT04312594

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 91 (actual)
• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized, double-blinded, and placebo-controlled phase II study to evaluate the efficacy and safety of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis.

Conditions

• Idiopathic Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	Jaktinib Hydrochloride Tablets	Patients were administered Jaktinib taken orally as tablets twice daily
DRUG	Jaktinib Hydrochloride Tablets	Patients were administered Jaktinib taken orally as tablets twice daily
DRUG	Placebo	Patients were administered Placebo taken orally as tablets twice daily

Timeline

• Start date: 2020-09-08
• Primary completion: 2022-06-09
• Completion: 2022-06-09
• First posted: 2020-03-18
• Last updated: 2024-12-12

Locations

1 site across 1 country: China